Passage Bio Inc (PASG) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PASG Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Passage Bio Inc balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent24.16
Cash & Short-term Investments24.00
Other Current Assets0.25
Prepaid Expense And Other Assets Current0.77
Total Current Assets25.18
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Prepaid Research And Development Asset Current0.72
Operating Lease Right Of Use Asset0.65
Total Assets25.18
Liabilities
Accounts Payable, Current AC0.90
Accrued Liabilities, Current1.37
Other Liabilities, Current18.45
Total Current Liabilities20.72
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Accrued Expenses And Other Current Liabilities3.90
Operating Lease Liability Noncurrent4.61
Total Liabilities20.72
Stockholders' Equity
Additional Paid In Capital Common Stock724.59
Retained Earnings / Accumulated Deficit-720.14
Common Stockholder's Equity4.46
Total Stockholder's Equity4.46
Liabilities & Stockholder's Equity25.18
4 historic quarters locked

Sign in to unlock the full Passage Bio Inc balance sheet history.

About Passage Bio Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-093021

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.